Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ES 014

Next Previous
Drug Profile

ES 014

Alternative Names: ES-014

Latest Information Update: 12 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elpiscience Biopharmaceuticals
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD39 antigen inhibitors; T lymphocyte stimulants; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Aug 2024 Cancer Institute and Hospital plans a phase II trial for Solid tumours(Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in China(IV, Infusion) (NCT06543056) in August 2024
  • 05 Nov 2023 Pharmacodynamics data from preclinical studies in Solid tumours released by Elpiscience Biopharmaceuticals
  • 20 Sep 2023 Adverse events, pharmacokinetics and pharmacodynamics data from a preclinical trial in Solid tumours presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top